Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Commercial lot versus phase III clinical lot of GSK 10-valent pneumococcal conjugate vaccine in infants
2014-000101-12Phase 3
- Sponsor
- GSK
- Start
- May 2015
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of 10-valent pneumococcal conjugate vaccine in pneumococcal disease (2 arms), sponsored by GSK. Primary endpoint: Antibody concentrations against vaccine components of the investigational pneumococcal conjugate vaccine.
02
Drugs
10-valent pneumococcal conjugate vaccine
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on 2014-000101-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000101-12.